Press releases

October 19, 2018

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

June 22, 2018

Advanced Accelerator Applications Announces First Patients Dosed in Two Clinical Studies with PSMA-R2 for Prostate Cancer – Second Theragnostic Program for Oncology Enters the Clinic

June 7, 2018

Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs

February 12, 2018

Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer

February 1, 2018

Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer

January 26, 2018

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

January 22, 2018

Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer

December 7, 2017

Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer

December 5, 2017

Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis

November 17, 2017

Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017

October 30, 2017

Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis

September 29, 2017

Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors

September 6, 2017

Advanced Accelerator Applications Announces First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate (Lutathera®)

August 31, 2017

Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017

August 28, 2017

Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera®)

July 27, 2017

Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA

July 21, 2017

Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors

May 31, 2017

Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017

May 30, 2017

Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin™ (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer

May 25, 2017

Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors

May 18, 2017

Advanced Accelerator Applications Receives 2017 Industry Innovation Award from National Organization for Rare Disorders for NETSPOT®, a Diagnostic Drug for Neuroendocrine Tumors

March 30, 2017

Advanced Accelerator Applications Signs Strategic Supply Agreement with University of Missouri for Lutetium 177

March 23, 2017

Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT® Launch Success

March 15, 2017

Advanced Accelerator Applications to Announce Full-Year 2016 Financial Results on March 23

March 6, 2017

Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS